Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
Authors:
- Charlotte E. TeunissenCTCharlotte E. Teunissen
- Martin P. J. van BoxtelMBMartin P. J. van Boxtel
- Jellemer JollesJJJellemer Jolles
- Jan de VenteJVJan de Vente
- Fred VreelingFVFred Vreeling
- Frans VerheyFVFrans Verhey
- Chris H. PolmanCPChris H. Polman
- Christine D. DijkstraCDChristine D. Dijkstra
- Henk J. BlomHBHenk J. Blom
- 1 January 2005
- journal article
- conference paper
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 43 (10) , 1089-1095
Abstract
Elevated serum homocysteine has been associated with increased risk of Alzheimer's disease. Furthermore, elevated homocysteine levels are related to cognitive dysfunction in the elderly. The aim of the present study was to explore the disease specificity of the relation between serum total homocysteine levels and cognitive function. For this, we summarize data from several studies on homocysteine levels in both normal and pathological conditions performed in our laboratories and evaluate possible mechanisms of effects of elevated homocysteine levels in the central nervous system. Total homocysteine levels were measured in serum of: 1) healthy aging individuals; 2) patients with Alzheimer's and Parkinson's disease and patients with other cognitive disorders; and 3) patients with multiple sclerosis. Increased serum homocysteine concentration was related to worse cognitive performance over a 6-year period in the normal aging population (r=−0.36 to −0.14, p<0.01 for the Word learning tests; r=0.76, p<0.05 for the Stroop Colored Word test). Homocysteine was only increased in patients with Parkinson's disease on L-Dopa therapy (18.9 vs. 16.5μmol/L in healthy controls), and not in dementia patients. Homocysteine was elevated in patients with progressive multiple sclerosis (15.0μmol/L, n=39, compared to 12.0 μmol/L in 45 controls) and correlated to both cognitive and motor function (r=−0.33 and −0.33, p<0.05, respectively). The relationship between homocysteine and cognitive function in non-pathological and pathological situations indicates that changes in its levels may play a role in cognitive functioning in a broad spectrum of conditions.Keywords
This publication has 36 references indexed in Scilit:
- Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal FluidGerontology, 2005
- Biological markers in CSF and blood for axonal degeneration in multiple sclerosisThe Lancet Neurology, 2005
- Homocysteine and levodopaNeurology, 2004
- Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug ApproachesCurrent Medicinal Chemistry, 2003
- Homocysteine Elicits a DNA Damage Response in Neurons That Promotes Apoptosis and Hypersensitivity to ExcitotoxicityThe Journal of Neuroscience, 2000
- Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction?Journal Of Hypertension, 1998
- Seizures Induced by Homocysteine in Rats During OntogenesisEpilepsia, 1995
- Serum Cobalamin Deficiency Is Uncommon in Multiple SclerosisArchives of Neurology, 1994
- Inhibition of l-glutamate uptake into synaptic vesiclesNeuroscience Letters, 1992
- Cognitive dysfunction in multiple sclerosis.Neurology, 1991